EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
Susan E JorgeAntônio Roberto Lucena de AraujoHiroyuki YasudaZofia PiotrowskaGeoffrey R OxnardDeepa RangachariMark S HubermanLecia V SequistSusumu S KobayashiDaniel B CostaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
The report confirms that EGFR exon 20 mutations are dependent on Hsp90 and are readily inhibited by the Hsp90 inhibitor luminespib; a treatment strategy that has been pursued in a confirmatory clinical trial (NCT01854034) for this group of lung adenocarcinomas that currently represent an unmet clinical need in precision oncology.